Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics

By Lafeuille Marie-Hélène   Gravel Jonathan   Lefebvre Patrick   Fastenau John   Muser Erik   Doshi Dilesh   Duh Mei Sheng  

Journal of Medical Economics, Vol. 16, Iss. 11, 2013-11 ,pp. : 1290-1299

Informa Healthcare

Access to resources Recommend Favorite

Factors associated with statin selection among privately insured commercial and Medicare patients

By Zhao Zhenxiang   Bae Jay   Sponseller Craig A.   Zhu Yajun   Kryzhanovski Vladimir A.   LeNarz LeRoy A.  

Current Medical Research and Opinion, Vol. 29, Iss. 4, 2013-04 ,pp. : 395-404

Informa Healthcare

Access to resources Recommend Favorite

Atypical Neuroleptic Malignant Syndrome or Serotonin Toxicity Associated with Atypical Antipsychotics?

By  

Current Drug Safety, Vol. 4, Iss. 1, 2009-01 ,pp. : 84-93

Bentham Science Publishers

Access to resources Recommend Favorite

Adherence to dornase alfa treatment among commercially insured patients with cystic fibrosis

By Nasr Samya Z.  

Journal of Medical Economics, Vol. 16, Iss. 6, 2013-06 ,pp. : 801-808

Informa Healthcare

Access to resources Recommend Favorite

Perceptions and prescribing considerations among US psychiatrists regarding drug–drug interactions associated with oral atypical antipsychotics

By Frois Christian   Guerin Annie   Saraogi Amit   Panish Jessica   Dirani Riad  

Current Medical Research and Opinion, Vol. 26, Iss. 12, 2010-12 ,pp. : 2735-2744

Informa Healthcare

Access to resources Recommend Favorite